Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

Université de Sherbrooke

$24,000.00

Development of an immune imaging method to accurately determine the immune status of tumors

FY 2021-22

Summary
Modern non-invasive imaging is integral to advancing our knowledge of biological processes and disease assessment. Molecular imaging takes the concept of imaging a step further by quantifying the amount and/or function of a specific marker of interest. Because of their high affinity toward cognate antigens, antibodies (Abs) are useful agents for both molecular imaging and therapy. The field of oncology has benefited from Ab-based immunotherapies because numerous antigens have been identified that are overexpressed on certain types of cancer cells compared to normal tissues. Labeling of Abs with radioisotopes can provide an important development for the field by identifying the appropriate target non-invasively. A major challenge with implementation of molecular Ab imaging is to achieve a high contrast signal to background ratio. This will depend on a number of variables including the form of the antibody (variable fragments, single chain variable fragments), the antibody clone, the radioisotope, the chelator and the imaging capabilities. In addition, biological systems will always have an inherent level of unspecific Ab uptake that can be attributed to vascular permeability and which can vary as a function of time and treatment. The objective of our research is to develop adequate methods for precise quantification of Abs in vivo. We will label antibodies against programmed-death ligand-1 (PDL1) with 89Zr, a long-lived PET radioisotope. An originality of our compound is the chelator 4HMSA, which chelates 89Zr more stably compared to standard chelators used for Ab labelling. We will explore pharmacokinetic methods to correct - subject-wise - for the unspecific uptake of the PDL1 tracer. We will also assess vascular permeability by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to determine a correction factor for non-specific tracer uptake. Our research will test the combined application of PET/DCE-MRI for imaging PDL1 in vivo in mouse models of cancer. The long term objective of this program is to: develop quantitative tools and methods to measure immune-related cell surface marker expression, immune cell composition of tissues and the immune response as a whole in cancer model systems. These imaging tools are lacking and would greatly benefit the field of oncology by enabling longitudinal monitoring of the local immune response in various cancers. Our program will provide a base for the design and analysis of new radiolabeled Abs which will expand the number of medical conditions that can benefit from diagnostic PET and MR imaging. Our program is designed such that training of HQP is a cornerstone of advancing our research. The interdisciplinary nature of our research will allow trainees to acquire a unique combination of skills from immunology, radiochemistry, radiobiology and biomedical imaging. The methods we will develop are adaptable to imaging other Abs and therefore can have wide applications in science and medicine.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2020-06156
Name nom
Oweida, Ayman
Department département
Department of Nuclear Medicine and Radiobiology
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2020
Award amount
24000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1505
Committee name en
Physics
Committee name fr
Physique
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
3114
Research subject group en
Physics
Research subject group fr
Physique
Research subject en
Biological and Medical Physics
Research subject fr
Physique biologique et médicale
Installment
inst:2
Partie
1
Nb partie
5
Application title
Development of an immune imaging method to accurately determine the immune status of tumors
Keyword
NSERC
Application summary
Modern non-invasive imaging is integral to advancing our knowledge of biological processes and disease assessment. Molecular imaging takes the concept of imaging a step further by quantifying the amount and/or function of a specific marker of interest. Because of their high affinity toward cognate antigens, antibodies (Abs) are useful agents for both molecular imaging and therapy. The field of oncology has benefited from Ab-based immunotherapies because numerous antigens have been identified that are overexpressed on certain types of cancer cells compared to normal tissues. Labeling of Abs with radioisotopes can provide an important development for the field by identifying the appropriate target non-invasively. A major challenge with implementation of molecular Ab imaging is to achieve a high contrast signal to background ratio. This will depend on a number of variables including the form of the antibody (variable fragments, single chain variable fragments), the antibody clone, the radioisotope, the chelator and the imaging capabilities. In addition, biological systems will always have an inherent level of unspecific Ab uptake that can be attributed to vascular permeability and which can vary as a function of time and treatment. The objective of our research is to develop adequate methods for precise quantification of Abs in vivo. We will label antibodies against programmed-death ligand-1 (PDL1) with 89Zr, a long-lived PET radioisotope. An originality of our compound is the chelator 4HMSA, which chelates 89Zr more stably compared to standard chelators used for Ab labelling. We will explore pharmacokinetic methods to correct - subject-wise - for the unspecific uptake of the PDL1 tracer. We will also assess vascular permeability by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to determine a correction factor for non-specific tracer uptake. Our research will test the combined application of PET/DCE-MRI for imaging PDL1 in vivo in mouse models of cancer. The long term objective of this program is to: develop quantitative tools and methods to measure immune-related cell surface marker expression, immune cell composition of tissues and the immune response as a whole in cancer model systems. These imaging tools are lacking and would greatly benefit the field of oncology by enabling longitudinal monitoring of the local immune response in various cancers. Our program will provide a base for the design and analysis of new radiolabeled Abs which will expand the number of medical conditions that can benefit from diagnostic PET and MR imaging. Our program is designed such that training of HQP is a cornerstone of advancing our research. The interdisciplinary nature of our research will allow trainees to acquire a unique combination of skills from immunology, radiochemistry, radiobiology and biomedical imaging. The methods we will develop are adaptable to imaging other Abs and therefore can have wide applications in science and medicine.